Epsilogen
James Birtley has worked in a variety of roles since 2002. Starting as a Lecturer at Birkbeck, University of London, they then took a Senior Financial Consultant role at Nationwide Building Society in 2005. In 2007, they began a Postdoctoral Researcher role at The University of Manchester and then moved to NCSR "DEMOKRITOS" in 2009 as a Postdoctoral Researcher - Marie Curie Fellow. In 2012, they became a Postdoctoral Researcher at UMass Medical School and in 2017, they began their current role as Principal Scientist at UCB. In 2022, they will move to Epsilogen Ltd as Principal Scientist.
James Birtley attended The University of Edinburgh from 1994 to 1999, where they earned a BSC Hons in Molecular Biology. James then went on to The University of Edinburgh from 1999 to 2000, where they earned a Master of Science in Molecular Genetics. After that, they attended Imperial College London from 2000 to 2005, where they earned a Doctor of Philosophy in Structural Biology. Finally, they attended The London Institute of Banking & Finance in 2006, where they earned a Certificate for Financial Advisors (CeFA) in Finance, General.
This person is not in any offices
Epsilogen
1 followers
Epsilogen is a global leader in the development of immunoglobulin (IgE) antibodies to treat cancer. IgE has several key features that make it ideal for the treatment of solid tumours including greater potency, enhanced tumour access and a long tissue half-life.